Agreements

Date: 2017-07-10

Type of information: Research agreement

Compound: T cell therapies

Company: Crispr Therapeutics (Switzerland - UK) Neon Therapeutics (USA - MA)

Therapeutic area: Cancer - Oncology

Type agreement: research

Action mechanism: cell therapy/immunotherapy product

Disease:

Details:

• On July 10, 2017, CRISPR Therapeutics and Neon Therapeutics announced a research collaboration to develop novel T cell therapies. This collaboration will explore gene-based technologies from CRISPR Therapeutics to generate potent T cell therapies directed against neoantigens.

Financial terms:

Latest news:

TOP